Elon Musk begins "recruiting" humans to test his Neuralink chips.

Neuralink has officially approved testing the N1 brain chip in paralyzed patients. This implant will allow controlling external devices with a person's thoughts.

Neuralink, Elon Musk's brain implant company, announced ultra-thin threads brain signal reading implants chip, approval by an institutional review board to test the brain chip in paralyzed patients.

Precise Robotically Implanted Brain-Computer Interface

The first test is called the "PRIME study" ( Precise Robotically Implanted Brain-Computer Interface ), an innovative investigational medical device trial for brain-computer interface (BCI). ) wireless and implantable, and its objectives are to evaluate the safety of the N1 implant and assess its functionality to "allow people with paralysis the possibility of controlling external devices with their thoughts."

Brain Implant Chip

Neuralink, Elon Musk's brain implant company, announced yesterday, September 19, approval by an institutional review board to test the brain chip in paralyzed patients.
The first test is called the "PRIME study" ( Precise Robotically Implanted Brain-Computer Interface ), an innovative investigational medical device trial for brain-computer interface (BCI). ) wireless and implantable, and its objectives are to evaluate the safety of the N1 implant and assess its functionality to "allow people with paralysis the possibility of controlling external devices with their thoughts."

Conclusion

According to Neuralink, during the study, the R1 robot will surgically place the ultra-thin, flexible threads of the N1 implant into a region of the brain that controls movement intention. Once established, the implant is intended to record and transmit brain signals wirelessly to an app that decodes the meaning of the movement.
On the other hand, Elon Musk's company points out that patients with paralysis due to cervical spinal cord injury or amyotrophic lateral sclerosis can participate in the test. Additionally, in the statement, Neuralink gives the option to join its patient registry to "qualify current and future clinical trials."